ArticleScientific reports2025
TIPE2 combined with immune cell infiltration predicts prognosis in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumor-associated neutrophils and survival outcomes in colorectal cancer: a systematic review and multilevel meta-analysis.Frontiers in oncology · 2026Pooled it
- TIPE2 knockdown enhances the anti-tumor efficacy of NKG2D CAR-T cells against pancreatic cancer via activating NF-κb signaling pathway.Journal of translational medicine · 2026Article
- A Pan-Cancer Atlas of TIPE2 Identifies Its Association With the Tumor Immune Microenvironment, Prognosis, and Immunotherapeutic Potential.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The incidence of colorectal cancer has shown an obvious upward trend worldwide. The prognostic prediction of CRC has not been well established. Based on immunohistochemistry staining, the expression and scoring of TIPE2 and CD8, CD20, and CD66b were evaluated and grouped. The clinicopathological parameters and IHC scores were analyzed and showed by Kaplan-Meier plots. High TIPE2 expression in CRC and normal tissues correlated with a better OS. In contrast, high CD8 and CD20 expression in CRC and normal tissues correlated with a worse OS. High CD66b expression in normal tissues was associated with a worse OS. Lasso and Cox analysis showed that N-stage, CA199, and CD8 in adjacent normal tissues were independent risk factors for OS. Grade and TIPE2 expression in cancer tissues were independent protective factors for OS in CRC patients. Moreover, the nomogram was constructed to predict the 1-, 3- and 5-year overall survival and validated by the calibration curves, receiver operating characteristic curves and decision curve analysis curves. Correlation analysis revealed that TIPE2 and CD8 were positively associated with PD-1 and TIM-3, indicating a potential link between TIPE2 and T cell exhaustion in colorectal cancer. TIPE2 combined with immune markers such as CD8, CD20, and CD66b in the TME can be used as biomarkers of disease progression and prognosis in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.